Informed Consent Translation in LATAM Clinical Trials: What Regulators Actually Reject

The document regulators read most carefully is the one most sponsors translate least carefully

Every clinical trial submission includes an informed consent form. And in every multi-country LATAM submission I have worked on, the ICF is the document most likely to generate a regulatory query, an ethics committee objection, or an outright rejection.

Not the IB. Not the protocol synopsis. The informed consent.

The reason is straightforward: regulators and ethics committees in Latin America treat the ICF as a patient-protection instrument, not an administrative formality. They read it. They compare it against local legal frameworks. And they reject it when the language does not meet standards that most translation vendors have never been briefed on.

This is the gap that costs sponsors 30 to 90 days per country. Not because the translation is wrong. Because it is right in the wrong way.

Why standard medical translation fails on informed consent

Most translation vendors approach an ICF the same way they approach a clinical study report or an investigator brochure: translate the source accurately, maintain consistency with the glossary, deliver on time.

For regulatory documents, that process works. For informed consent, it does not. Here is why.

An informed consent form is not a regulatory document. It is a legal document, a patient communication document, and a regulatory document simultaneously. The translation must satisfy three different audiences with three different expectations:

1. The regulator needs to verify that the translated ICF matches the approved protocol and complies with local informed consent regulations
2. The ethics committee needs to confirm that the language is comprehensible to the target patient population, including literacy-adjusted readability
3. The patient needs to actually understand what they are consenting to

A translation that satisfies the regulator but not the ethics committee gets sent back. A translation that satisfies the ethics committee but deviates from local legal phrasing gets flagged by the regulator. A translation that satisfies both but reads at a university literacy level in a country where trial participants average a sixth-grade education gets rejected on ethical grounds.

Generic translation vendors optimize for one audience. Regulatory translation requires satisfying all three simultaneously.

What each LATAM regulator actually flags on ICF translations

After processing informed consent translations across nine LATAM jurisdictions, these are the patterns that generate the most queries and rejections.

Brazil (ANVISA / CONEP)

Brazil's CONEP (National Research Ethics Commission) is the most demanding ethics body in LATAM for informed consent review. The TCLE (Termo de Consentimento Livre e Esclarecido) must be in Brazilian Portuguese — not European Portuguese — and must use language accessible to the specific patient population.

CONEP routinely rejects ICFs that:

• Use technical terms without lay-language explanations in parentheses
• Translate "randomization" literally without explaining the concept in plain language
• Fail to include specific Brazilian legal rights (the right to withdraw without prejudice must use exact statutory language from Resolution 466/2012)
• Present risks in a format that CONEP considers minimizing (bullet points without probability context are flagged)

The most common rework trigger: sponsors translate the English ICF into Portuguese and assume CONEP will accept it. CONEP expects a document that reads as if it were originally written for a Brazilian patient, not translated from English.

Mexico (COFEPRIS)

COFEPRIS reviews the ICF against the General Health Law and NOM-012-SSA3-2012. The translation must use Mexican Spanish medical terminology, which diverges from Castilian Spanish and other regional variants in clinically significant ways.

Common rejection triggers:

• Using "aleatorización" (Castilian) instead of the phrasing COFEPRIS expects in context
• Omitting mandatory clauses about the patient's right to receive information about the study results
• Translating compensation language that conflicts with Mexican regulations on trial participant payment
• Failing to match the specific consent withdrawal language that Mexican ethics committees require

Colombia (INVIMA)

INVIMA requires ICF translations to comply with Resolution 8430 of 1993. The most frequent rejection: translations that do not adapt the confidentiality section to reference Colombian data protection law (Ley 1581 de 2012, Habeas Data).

INVIMA ethics committees also flag ICFs where the risk-benefit explanation does not follow the structure prescribed by Colombian research ethics guidelines. A technically accurate translation that does not follow the expected disclosure sequence gets returned.

Argentina (ANMAT)

ANMAT reviews ICFs through provincial ethics committees, which means a single trial may face different ICF expectations across Buenos Aires, Córdoba, and Mendoza. The translation must use Argentine Spanish (voseo forms are expected in patient-facing language) and must include specific references to Ley 25.326 (Personal Data Protection).

The most overlooked requirement: Argentina expects the ICF to include an explicit statement about biological sample handling that many English-source ICFs do not contain. If the source document lacks it, the translation must add it — which means the translator needs to know Argentine regulatory requirements, not just Spanish.

Peru (DIGEMID), Chile (ISP), Ecuador (ARCSA), Panama (DNM), Costa Rica (SRS)

Each of these regulators has jurisdiction-specific ICF requirements that create translation traps:

• Peru requires Quechua or Aymara translations for trials conducted in indigenous communities, in addition to Spanish
• Chile requires specific language about the public health system's role in adverse event management
• Ecuador mandates references to the Organic Health Law in the rights disclosure section
• Panama requires alignment with Ley 84 de 2019 on clinical research
• Costa Rica has among the most prescriptive ethics committee requirements in the region, with specific formatting and section-ordering expectations

The real cost of ICF translation failures

When an ICF is rejected or queried, the cost is not the retranslation. The cost is the delay.

A single ethics committee query on an ICF in Brazil can add 45 to 60 days to the approval timeline. In Colombia, an INVIMA rejection on consent language can push a study start by 30 to 90 days. Multiply that across a multi-country trial filing in five or six LATAM markets simultaneously, and a consent form translation failure can shift an entire regional enrollment timeline by a quarter.

I have seen a Phase III oncology trial lose its enrollment window in Brazil — a $2.1 million impact — because the TCLE was translated by a vendor that did not know CONEP's plain-language requirements. The translation was linguistically flawless. It was regulatorily useless.

What first-pass acceptance on ICF translation actually requires

Getting informed consent translations accepted on first submission across multiple LATAM regulators requires a process that most translation workflows are not built for:

Jurisdiction-specific legal mapping. Before translation begins, every mandatory legal clause, statutory reference, and rights disclosure must be mapped for each target country. The translator works from a regulatory brief, not just a source document.

Readability calibration. The translated ICF must meet the literacy expectations of the target patient population in each country. This is not a post-translation review step. It is built into the translation itself.

Ethics committee pattern matching. Each ethics committee has institutional preferences for how information is structured, disclosed, and formatted in an ICF. Translators who have processed prior submissions through the same committee know these patterns. Translators who have not will learn them through rejection.

Back-translation with regulatory context. Back-translation is required by most LATAM regulators. But a back-translation that proves linguistic accuracy without demonstrating regulatory compliance is insufficient. The back-translator must flag deviations from local requirements, not just deviations from the source text.

This is what regulatory translation infrastructure means in practice. Not a better translation. A translation built on top of regulatory intelligence that most vendors do not have.

The informed consent is the submission's front door

Regulators in LATAM read the ICF first because it tells them whether the sponsor understands the local regulatory environment. A well-translated ICF signals competence. A poorly translated one signals risk — and regulators respond accordingly, often scrutinizing the rest of the dossier more aggressively.

The informed consent is not a formality. It is the document that sets the regulatory tone for the entire submission.

Treat it accordingly.

Frequently asked questions

Related reading